61.   SmithKline led the drop in European pharmaceutical stocks after the U.S. Food and Drug Administration requested modifications to its license application for Bexxar leukemia treatment.

62.   Tech and pharmaceutical stocks fell amid earnings warnings from analysts Tuesday, while the broader market drifted in lackluster trading.

63.   The Dow was pulled lower by losses in pharmaceutical stocks, a sector usually popular in times of economic uncertainty.

64.   The Nikkei later moved into positive territory with some buying of technology issues and pharmaceutical stocks.

65.   Also vulnerable to the effect of currency movements, pharmaceutical stocks were affected.

66.   Despite the drop in the broader market, consumer product and pharmaceutical stocks remained strong.

67.   Other pharmaceutical stocks were higher too, although dealers attributed those gains to sector rotation.

68.   Pharmaceutical stocks rebounded from previous falls, despite a poor performance by the sector in New York overnight.

69.   Pharmaceutical stocks rose in response to a six-percent rise in world drugs sales in the first half of the year.

70.   Pharmaceutical stocks rose on overnight gains in New York.